Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 901 - 950 out of 12,304

Document Document Title
WO/2011/158904A1
Disclosed is an effective and safe therapeutic agent for inflammatory diseases such as sepsis, pneumonia, and inflammatory bowel diseases, which contains adenosine N1-oxide or a derivative thereof as an active ingredient.  
WO/2011/134444A3
The invention relates to substitution derivatives of N6-benzyladenosine-5'- monophosphate of the general formula I, wherein (R)n represents 1 to 4 substituents (n is in the range 1 - 4), which can be the same or different, and R is selec...  
WO/2011/159471A2
The disclosure provides linked purine pterin compounds and analogues thereof that are novel HPPK inhibitors. The HPPK inhibitors described herein are compounds and the pharmaceutically acceptable salts thereof of general Formula I: (I). ...  
WO/2011/156278A1
The present invention provides novel 3', 5 '-linked bicyclic nucleosides and oligomeric compounds prepared therefrom. The bicyclic nucleosides provided herein are useful for enhancing one or more properties of the oligomeric compounds th...  
WO/2011/153874A1
Provided is a crystallization process of cyclic adenosine 3',5'-monophosphate, which comprises the following steps: 1) reacting an aqueous solution of cyclic adenosine 3',5'-monophosphate with a base to obtain a salt of cyclic adenosine ...  
WO/2011/156202A1
Provided herein are 2'-amino and 2'-thio bicyclic nucleosides and oligomenc compounds prepared therefrom. The novel bicyclic nucleosides provided herein are expected to be useful for enhancing one or more properties of the oligomeric com...  
WO/2011/152155A1
Disclosed is a method for producing a (2R)-2-fluoro-2-C-methyl-D-ribono-γ-lactone precursor of an open-ring fluorinated compound [In the formula, Me represents a methyl group, R1 represents an alkyl group or an alkyl substituent, P1 and...  
WO/2011/151493A1
The invention relates to glycosylated derivatives of formula I, wherein the designations for the each substituent are indicated in the description. Said compounds can be used as α-glycosidase inhibitors.  
WO/2011/143593A1
The invention provides conjugate compounds, pharmaceutical compositions, therapeutic methods, and kits for use in treating cell proliferation disorders, such as cancer. The conjugates comprise a redox-modulating compound, such as a lipoi...  
WO/2011/078797A3
The present invention refers to an antisense oligonucleotide having a L3 score of about < 0.1; a L4_OR(5´) score of about < 0.15; a L4_OR(3´) score of about < 0.12; a PESE score of about > 70 %; and the antisense oligonucleotide binds ...  
WO/2008/062206A8
Phosphoramidate derivatives of nucleoside compounds of formula I derived from bases such as adenine and guanine have enhanced therapeutic potency, in particular, enhanced potency with respect to the prophylaxis or treatment of a viral in...  
WO/2011/133871A2
The present invention provides compounds of formula (1). Another aspect of the invention relates to a method of inhibiting the expression of a gene in call, the method comprising (a) contacting an oligonucleotide of the invention with th...  
WO/2011/132801A1
Disclosed is a nucleic acid base analog with quenching characteristics and fluorescence and application thereof. Specifically disclosed is a quencher characterized by having a 2-nitropyrrole structure shown by formula (I). [In formula (I...  
WO/2011/130289A1
The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making...  
WO/2011/060408A3
The present invention relates to 2'-Fluoro-6'-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease...  
WO/2011/123672A1
Disclosed herein is a compound represented by formula 1 or its hydrate thereof in crystalline or crystal-like form.  
WO/2011/123668A2
Disclosed herein are phosphorus-containing actives, their use as actives for treating diseases, and a stereoselective process for preparing the same. Also disclosed herein are useful synthetic intermediates and processes for preparing th...  
WO/2011/123645A2
Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitor...  
WO/2011/119674A1
Disclosed are compositions and methods related to modified nucleobases. Also disclosed are compositions and methods related to modified interfering RNAs. Also disclosed are compositions and methods related to modified adenonsine for cont...  
WO/2011/119969A1
Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is direct...  
WO/2011/002200A3
The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition havi...  
WO/2011/119919A1
The present invention is directed to a benzyloxy cyclopentyladenosine (BCPA) compounds and to their use as selective Ai adenosine receptor agonists. The compounds of the invention are particularly directed to use in subjects for reducing...  
WO/2011/115513A2
This invention provides a cytosine analogue, a method of preparation of a cytosine analogue, a DNA rhethyltransferase 1 inhibitor, a method for DNA methylation inhibition, the use of the analogue in the treatment of diseases associated w...  
WO/2011/113174A1
Cytarabine derivatives obtained by chemically modifying N4 and O5 position of cytarabine are provided. Methods for synthesizing the cytarabine derivatives, the formulations comprising the cytarabine derivatives and their preparation meth...  
WO/2011/115817A1
Provided herein are methods for preparing 2'-O-substituted purine nucleosides without protecting exocyclic amino groups on the base during alkylation. The methods are particularly useful in that the products are crystalline enabling puri...  
WO/2011/113175A1
The cytarabine prodrug derivatives of general formulas (I), (II) and (III), their synthetic routes, preparations and preparative methods thereof, and use for resisting cancer or tumor. The derivatives are prepared by chemical modificatio...  
WO/2011/115818A1
Provided herein are novel 5'-(S)-CH3 substituted bicyclic nucleosides, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, the furanose ring of each of the novel 5'-(S)-CH3 substitute...  
WO/2011/113173A1
The cytarabine prodrug derivatives of general formula (I), their synthetic routes, preparation and preparative method thereof, and use for resisting cancer or tumor. The derivatives are prepared by chemical modification on N4, O5 positio...  
WO/2011/112947A1
Embodiments of the invention are directed to compositions and methods that use non- extendable oligonucleotides to enhance or improve synthesis or amplification of nucleic acids.  
WO/2011/111501A1
Disclosed is RNA that includes a translated region having a 5' cap structure as well as a 5' side start codon and 3' side stop codon on the ends. A nucleoside compound in which a group represented by formula (I) is bonded to position 8 o...  
WO/2011/108682A1
A phosphorothioate RNA manufacturing method that uses an oxazaphospholidine approach is characterised by the use of a cyanoethoxymethyl group instead of a tert-butyldimethylsilyl group as the protecting group for the 2' hydroxyl group of...  
WO/2011/051733A3
The present invention relates to compounds and their use in competitive protein binding assays, for example for use with glycosyl transferase and/or glycoprocessing proteins. The present application also provides kits and apparatuses for...  
WO/2011/104540A1
The present invention relates a one step process for the preparation of capecitabine and analogues thereof, such as galocitabine, sapacitabine, 5'-deoxy-5-fiuoro-N- [(cyclohexyloxy)carbonyl]cytidine, and N-[(heptyloxy)carbonyl]cytarabine.  
WO/2011/103468A2
The present invention provides building blocks and methods for synthesizing very pure RNA in a form that can efficiently be modified at the 3' end. Reverse RNA monomer phosphoramidites have been developed for RNA synthesis in 5'-> 3' dir...  
WO/2011/099443A1
Disclosed is a method for producing a β-dihydrofuran deriving compound or a β-tetrahydrofuran deriving compound represented by formula (1) or (4), which is characterized by having a dialkyl dicarbonate, a diaralkyl dicarbonate or a hal...  
WO/2011/092158A1
Compounds having the formula I wherein R1, R2 and R3 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.  
WO/2011/005595A3
Disclosed herein are compounds that activate RNaseL, methods of synthesizing compounds that activate RNaseL and the use of compounds that activate RNaseL for treating and/or ameliorating a disease or a condition, such as a viral infectio...  
WO/2011/090052A1
Disclosed is a novel phosphorylation reagent. Specifically disclosed is a compound represented by general formula (A). In the formula, WG1 and WG2 independently represent a cyano group, a nitro group, a halogen atom, an alkylsulfonyl gro...  
WO/2011/085701A1
Protein kinase activators, hydrates of adenosine cyclophosphate salt, preparation methods and uses thereof are disclosed. The hydrates of adenosine cyclophosphate salt have excellent storage stability and are not liable to absorb moistur...  
WO/2011/032034A3
Embodiments are disclosed herein that involve C5-functionalized nucleic acids, which can be used for detecting a target in a nucleic acid. Particular embodiments disclose methods for making these compounds, wherein the compounds can be f...  
WO/2011/083484A2
The present invention relates to improved process for the preparation of lamivudine or emtricitabine. Thus, (1'R,2'S,5'R)-menthyl- 5(R,S)-acetoxy-[1,3]-oxathiolane-2(R)-carboxylate is reacted with N-propinoyl cytosine in hexamethyl disil...  
WO/2008/060632A3
The invention provides substituted 5'-bi- tri- or tetraphosphate ribose analog compounds that act at P2Y receptors, e.g., the P2Y2 receptor, including pharmaceutical compositions; and uses thereof to treat or prevent diseases associated ...  
WO/2009/102928A3
The invention provides compounds and methods for making adenosine-ribofuranoside tetraphosphate compounds. The compounds are contemplated to have activity at the P2Y receptor and may be used in the treatment of medical disorders such as ...  
WO/2011/079501A1
Prodrugs based on cytarabine structure shown as formula (I) as well as their synthetic method and application are disclosed, wherein the definitions for the groups of R1 and R2 are described in the specification. The solubility, the bioa...  
WO/2011/077095A1
There is provided compounds of formula (I), wherein R1, R2, X1, X2, and X3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as positron emission tomography (PET) imaging ag...  
WO/2011/048148A3
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...  
WO/2011/075052A1
The present invention includes novel 3´-deoxy-3´-methylidene-β-L-nucleosides, pharmaceutical composition comprising such compounds, as well as the methods to treat or to prevent viral infections and in particular HBV and/or HIV infect...  
WO/2011/074675A1
Provided is a process for the preparation of a spiroketal derivative via a compound represented by general formula (II) [wherein each variable group and each variable number are as defined in the description].  
WO/2006/012440A8
The present invention provides (i) a process for preparing a 2-deoxy-2-fluoro-2-methyl-D-ribonolactone derivative, (ii) conversion of the lactone to nucleosides with potent anti-HCV activity, and their analogues, and (iii) a method to pr...  
WO/2011/069294A1
The present invention provides N6-substituted adenosine derivatives, N6-substituted adenine derivatives, manufacturing methods thereof, a pharmaceutical composition comprising said compounds above, and the uses of these compounds in manu...  

Matches 901 - 950 out of 12,304